Literature DB >> 31711169

Targeting MEK/MELK in atypical teratoid rhabdoid tumor: a treatment approach aimed at exploiting blood-brain barrier deficiencies.

Dean Popovski1, Annie Huang1,2,3,4.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31711169      PMCID: PMC6954388          DOI: 10.1093/neuonc/noz217

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  9 in total

1.  M-phase MELK activity is regulated by MPF and MAPK.

Authors:  Caroline Badouel; Roman Körner; Marie Frank-Vaillant; Anne Couturier; Erich A Nigg; Jean-Pierre Tassan
Journal:  Cell Cycle       Date:  2006-04-17       Impact factor: 4.534

2.  Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes.

Authors:  Pascal D Johann; Serap Erkek; Marc Zapatka; Kornelius Kerl; Ivo Buchhalter; Volker Hovestadt; David T W Jones; Dominik Sturm; Carl Hermann; Maia Segura Wang; Andrey Korshunov; Marina Rhyzova; Susanne Gröbner; Sebastian Brabetz; Lukas Chavez; Susanne Bens; Stefan Gröschel; Fabian Kratochwil; Andrea Wittmann; Laura Sieber; Christina Geörg; Stefan Wolf; Katja Beck; Florian Oyen; David Capper; Peter van Sluis; Richard Volckmann; Jan Koster; Rogier Versteeg; Andreas von Deimling; Till Milde; Olaf Witt; Andreas E Kulozik; Martin Ebinger; Tarek Shalaby; Michael Grotzer; David Sumerauer; Josef Zamecnik; Jaume Mora; Nada Jabado; Michael D Taylor; Annie Huang; Eleonora Aronica; Anna Bertoni; Bernhard Radlwimmer; Torsten Pietsch; Ulrich Schüller; Reinhard Schneppenheim; Paul A Northcott; Jan O Korbel; Reiner Siebert; Michael C Frühwald; Peter Lichter; Roland Eils; Amar Gajjar; Martin Hasselblatt; Stefan M Pfister; Marcel Kool
Journal:  Cancer Cell       Date:  2016-02-25       Impact factor: 31.743

3.  Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis.

Authors:  Jonathon Torchia; Daniel Picard; Lucie Lafay-Cousin; Cynthia E Hawkins; Seung-Ki Kim; Louis Letourneau; Young-Shin Ra; King Ching Ho; Tiffany Sin Yu Chan; Patrick Sin-Chan; Christopher P Dunham; Stephen Yip; Ho-Keung Ng; Jian-Qiang Lu; Steffen Albrecht; José Pimentel; Jennifer A Chan; Gino R Somers; Maria Zielenska; Claudia C Faria; Lucia Roque; Berivan Baskin; Diane Birks; Nick Foreman; Douglas Strother; Almos Klekner; Miklos Garami; Peter Hauser; Tibor Hortobágyi; Laszló Bognár; Beverly Wilson; Juliette Hukin; Anne-Sophie Carret; Timothy E Van Meter; Hideo Nakamura; Helen Toledano; Iris Fried; Daniel Fults; Takafumi Wataya; Chris Fryer; David D Eisenstat; Katrin Scheineman; Donna Johnston; Jean Michaud; Shayna Zelcer; Robert Hammond; David A Ramsay; Adam J Fleming; Rishi R Lulla; Jason R Fangusaro; Nongnuch Sirachainan; Noppadol Larbcharoensub; Suradej Hongeng; Muhammad Abrar Barakzai; Alexandre Montpetit; Derek Stephens; Richard G Grundy; Ulrich Schüller; Theodore Nicolaides; Tarik Tihan; Joanna Phillips; Michael D Taylor; James T Rutka; Peter Dirks; Gary D Bader; Monika Warmuth-Metz; Stefan Rutkowski; Torsten Pietsch; Alexander R Judkins; Nada Jabado; Eric Bouffet; Annie Huang
Journal:  Lancet Oncol       Date:  2015-04-14       Impact factor: 41.316

4.  MELK Promotes Melanoma Growth by Stimulating the NF-κB Pathway.

Authors:  Radoslav Janostiak; Navin Rauniyar; TuKiet T Lam; Jianhong Ou; Lihua J Zhu; Michael R Green; Narendra Wajapeyee
Journal:  Cell Rep       Date:  2017-12-05       Impact factor: 9.423

5.  Comprehensive Analysis of Chromatin States in Atypical Teratoid/Rhabdoid Tumor Identifies Diverging Roles for SWI/SNF and Polycomb in Gene Regulation.

Authors:  Serap Erkek; Pascal D Johann; Martina A Finetti; Yiannis Drosos; Hsien-Chao Chou; Marc Zapatka; Dominik Sturm; David T W Jones; Andrey Korshunov; Marina Rhyzova; Stephan Wolf; Jan-Philipp Mallm; Katja Beck; Olaf Witt; Andreas E Kulozik; Michael C Frühwald; Paul A Northcott; Jan O Korbel; Peter Lichter; Roland Eils; Amar Gajjar; Charles W M Roberts; Daniel Williamson; Martin Hasselblatt; Lukas Chavez; Stefan M Pfister; Marcel Kool
Journal:  Cancer Cell       Date:  2018-12-27       Impact factor: 31.743

6.  Disrupting LIN28 in atypical teratoid rhabdoid tumors reveals the importance of the mitogen activated protein kinase pathway as a therapeutic target.

Authors:  Melanie F Weingart; Jacquelyn J Roth; Marianne Hutt-Cabezas; Tracy M Busse; Harpreet Kaur; Antoinette Price; Rachael Maynard; Jeffrey Rubens; Isabella Taylor; Xing-Gang Mao; Jingying Xu; Yasumichi Kuwahara; Sariah J Allen; Anat Erdreich-Epstein; Bernard E Weissman; Brent A Orr; Charles G Eberhart; Jaclyn A Biegel; Eric H Raabe
Journal:  Oncotarget       Date:  2015-02-20

7.  Atypical teratoid rhabdoid tumor: improved long-term survival with an intensive multimodal therapy and delayed radiotherapy. The Medical University of Vienna Experience 1992-2012.

Authors:  Irene Slavc; Monika Chocholous; Ulrike Leiss; Christine Haberler; Andreas Peyrl; Amedeo A Azizi; Karin Dieckmann; Adelheid Woehrer; Christina Peters; Georg Widhalm; Christian Dorfer; Thomas Czech
Journal:  Cancer Med       Date:  2013-12-11       Impact factor: 4.452

8.  Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors.

Authors:  Jonathon Torchia; Brian Golbourn; Shengrui Feng; King Ching Ho; Patrick Sin-Chan; Alexandre Vasiljevic; Joseph D Norman; Paul Guilhamon; Livia Garzia; Natalia R Agamez; Mei Lu; Tiffany S Chan; Daniel Picard; Pasqualino de Antonellis; Dong-Anh Khuong-Quang; Aline C Planello; Constanze Zeller; Dalia Barsyte-Lovejoy; Lucie Lafay-Cousin; Louis Letourneau; Mathieu Bourgey; Man Yu; Deena M A Gendoo; Misko Dzamba; Mark Barszczyk; Tiago Medina; Alexandra N Riemenschneider; A Sorana Morrissy; Young-Shin Ra; Vijay Ramaswamy; Marc Remke; Christopher P Dunham; Stephen Yip; Ho-Keung Ng; Jian-Qiang Lu; Vivek Mehta; Steffen Albrecht; Jose Pimentel; Jennifer A Chan; Gino R Somers; Claudia C Faria; Lucia Roque; Maryam Fouladi; Lindsey M Hoffman; Andrew S Moore; Yin Wang; Seung Ah Choi; Jordan R Hansford; Daniel Catchpoole; Diane K Birks; Nicholas K Foreman; Doug Strother; Almos Klekner; Laszló Bognár; Miklós Garami; Péter Hauser; Tibor Hortobágyi; Beverly Wilson; Juliette Hukin; Anne-Sophie Carret; Timothy E Van Meter; Eugene I Hwang; Amar Gajjar; Shih-Hwa Chiou; Hideo Nakamura; Helen Toledano; Iris Fried; Daniel Fults; Takafumi Wataya; Chris Fryer; David D Eisenstat; Katrin Scheinemann; Adam J Fleming; Donna L Johnston; Jean Michaud; Shayna Zelcer; Robert Hammond; Samina Afzal; David A Ramsay; Nongnuch Sirachainan; Suradej Hongeng; Noppadol Larbcharoensub; Richard G Grundy; Rishi R Lulla; Jason R Fangusaro; Harriet Druker; Ute Bartels; Ronald Grant; David Malkin; C Jane McGlade; Theodore Nicolaides; Tarik Tihan; Joanna Phillips; Jacek Majewski; Alexandre Montpetit; Guillaume Bourque; Gary D Bader; Alyssa T Reddy; G Yancey Gillespie; Monika Warmuth-Metz; Stefan Rutkowski; Uri Tabori; Mathieu Lupien; Michael Brudno; Ulrich Schüller; Torsten Pietsch; Alexander R Judkins; Cynthia E Hawkins; Eric Bouffet; Seung-Ki Kim; Peter B Dirks; Michael D Taylor; Anat Erdreich-Epstein; Cheryl H Arrowsmith; Daniel D De Carvalho; James T Rutka; Nada Jabado; Annie Huang
Journal:  Cancer Cell       Date:  2016-12-12       Impact factor: 31.743

9.  MEK/MELK inhibition and blood-brain barrier deficiencies in atypical teratoid/rhabdoid tumors.

Authors:  Michaël H Meel; Miriam Guillén Navarro; Mark C de Gooijer; Dennis S Metselaar; Piotr Waranecki; Marjolein Breur; Tonny Lagerweij; Laurine E Wedekind; Jan Koster; Marianne D van de Wetering; Netteke Schouten-van Meeteren; Eleonora Aronica; Olaf van Tellingen; Marianna Bugiani; Timothy N Phoenix; Gertjan J L Kaspers; Esther Hulleman
Journal:  Neuro Oncol       Date:  2020-01-11       Impact factor: 12.300

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.